Previous 10 | Next 10 |
home / stock / mdgef / mdgef news
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumors CD40L-CD28 costimulatory switch receptor ...
Martinsried /M unich , April 27 , 202 3 . Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20 th Asso...
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levels No neurotoxicity or dose-limiting toxicities observed Two out of nine patients showed early response on treatment at week 4, of which one patient experienced disease progression ...
Martinsried /M unich, April 18 , 2023 , Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents preclinical data on MDG1015, a T cell r...
Martinsried/M unich , April 11 , 202 3 . Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the European Society...
Martinsried /M unich , April 04 , 202 3 . Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel, Me...
Martinsried /M unich , April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National Cancer Institute (NCI) will collaborate...
2023-03-29 14:42:04 ET Medigene AG (MDGEF) Q4 2022 Earnings Conference Call March 29, 2023 09:00 ET Company Participants Pamela Keck - Head of Investor Relations & Corporate Communications Selwyn Ho - Chief Executive Officer Conference Call Participants ...
2023-03-29 06:27:59 ET Medigene AG press release ( OTCPK:MDGEF ): FY GAAP EPS of -€0.34. Revenue of €31.25M (+198.8% Y/Y). For further details see: Medigene AG GAAP EPS of -€0.34, revenue of €31.25M
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate development Partnering momentum continues with a $3 million milestone payment from 2seventy bio Strengthened leadership with key hires in Cor...
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...